Immunmodulation und Neuroprotektion bei Neuritis nervi optici

• Verfasst von: Beisse, Flemming [VerfasserIn]
• Verfasst von: Diem, Ricarda [VerfasserIn]
• Titel: Immunmodulation und Neuroprotektion bei Neuritis nervi optici
• Titelzusatz: =
• Paralleltitel: Immunomodulation and neuroprotection in optic neuritis
• Verf.angabe: F. Beisse, R. Diem
• E-Jahr: 2016
• Jahr: 10. Mai 2016
• Umfang: 4 S.
• Fussnoten: Gesehen am 18.09.2019
• Titel Quelle: Enthalten in: Der Ophthalmologe
• Ort Quelle: Berlin : Springer, 1996
• Jahr Quelle: 2016
• Band/Heft Quelle: 113(2016), 5, Seite 398-401
• ISSN Quelle: 1433-0423
• DOI: doi:10.1007/s00347-016-0264-2
• Datenträger: Online-Ressource
• Sprache: ger eng
• Sach-SW: Amilorid
• Sach-SW: Amiloride
• Sach-SW: Anti-LINGO
• Sach-SW: Erythropoietin
• Sach-SW: human
• Sach-SW: LINGO-1 protein
• Sach-SW: Memantin
• Sach-SW: Memantine
• Sach-SW: Phenytoin
• K10plus-PPN: 1677280042

Abstract

Background To date, high-dose corticosteroids constitute the only established treatment of acute optic neuritis (ON); however, steroids cannot prevent the loss of retinal nerve fibers. New acute therapeutic drugs are therefore being sought for a reduction of ganglion cell death.MethodsLiterature search comprising clinical studies on treatment of ON with immunomodulatory and neuroprotective drugs.ResultsFor the immunomodulatory drug simvastatin some evidence for long-term benefits was shown, particularly regarding visual evoked potentials. For the neuroprotective substance memantine a potential positive effect on retinal nerve fiber layer (RNFL) thickness was revealed. Likewise in one publication a reduction in loss of RNFL thickness could be demonstrated for erythropoietin and this drug is currently being extensively investigated in a phase III randomized controlled trial (RCT). The results of studies with phenytoin, amiloride and anti-leucine-rich repeat and immunoglobulin domain containing 1 protein (anti-LINGO-1) antibodies are awaiting publication.ConclusionAccording to the data from recent treatment trials, there is hope that neuronal loss in ON can be reduced with the help of immunomodulatory substances, such as simvastatin or neuroprotective agents, such as memantine and erythropoietin.